Thus, targeting TSPO on top of mitotane administration might represent a promising pharmacological strategy to treat ACC patients, enabling to potentiate mitotane actions while reducing mitotane doses and minimizing potential side effects. Here, TSPO is linked to adrenal cortex carcinoma.